logo

For the Inventor, By the Inventor

Burnaby, Canada

Tekmira Pharmaceuticals Corporation


USPTO Granted Patents = 14

% Expired Patents = 35.7



Forward Citations = 1,172

Loading Chart...
Loading Chart...

31 inventors (with patents filed for the assignee):

goldMedal Kallanthottathil G Rajeev (9 out of 199 patents)

silverMedal Muthiah Manoharan (9 out of 327 patents)

bronzeMedal Muthusamy Jayaraman (9 out of 65 patents)

4.  David Butler (6 out of 37 patents)

5.  Jayaprakash K Narayanannair (4 out of 8 patents)

6.  Akin Akinc (3 out of 62 patents)

7.  Martin A Maier (3 out of 130 patents)

8.  Jianxin Chen (3 out of 15 patents)

9.  Thomas D Madden (3 out of 24 patents)

10.  Sean C Semple (3 out of 12 patents)

11.  Laxman Eltepu (2 out of 12 patents)

12.  Marco A Ciufolini (2 out of 19 patents)

13.  Michael J Hope (2 out of 40 patents)

14.  Steven Michial Ansell (2 out of 30 patents)

15.  Pieter Rutter Cullis (2 out of 73 patents)


14 patents:

1. 9801874 - Method for the preparation of liposome encapsulated vincristine for therapeutic use (2017-10-31),
2. 9345780 - Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components (2016-05-24),
3. 9220683 - Lipids and compositions for the delivery of therapeutics (2015-12-29),
4. 9186325 - Lipids and compositions for the delivery of therapeutics (2015-11-17),
5. 9139554 - Amino lipids and methods for the delivery of nucleic acids (2015-09-22),
6. 9051567 - Methods for increasing efficacy of lipid formulated siRNA (2015-06-09),
7. 8999351 - Lipids and compositions for the delivery of therapeutics (2015-04-07),
8. 8883202 - Lipid compositions (2014-11-11),
9. 8802644 - Lipid formulation (2014-08-12),
10. 8722082 - Lipids and compositions for the delivery of therapeutics (2014-05-13),
11. 8642076 - Lipid containing formulations (2014-02-04),
12. 8575123 - Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components (2013-11-05),
13. 7811602 - Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof (2010-10-12),
14. 7244448 - Liposomal antineoplastic drugs and uses thereof (2007-07-17),
Company Overview
Tekmira Pharmaceuticals Corporation, based in Burnaby, Canada, is a biopharmaceutical company focused on the development of innovative RNA interference (RNAi) therapeutics. The organization specializes in leveraging its proprietary lipid nanoparticle technology to deliver RNAi molecules for the treatment of various diseases, including viral infections and cancer. Tekmira's research emphasizes the potential of RNAi as a transformative approach in medicine, aiming to address unmet medical needs through targeted therapies.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

14 Patents

#30 in Burnaby

#1,067 in Canada

#42,249 in the World

Burnaby, CA
Burnaby, Canada

Tekmira Pharmaceuticals Corporation

Forward Citations = 1,172

31 inventors:

goldMedal Kallanthottathil G Rajeev (9 out of 199 patents)

silverMedal Muthiah Manoharan (9 out of 327 patents)

bronzeMedal Muthusamy Jayaraman (9 out of 65 patents)

4.  David Butler (6 out of 37 patents)

5.  Jayaprakash K Narayanannair (4 out of 8 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Tekmira Pharmaceuticals Corporation. Retrieved from https://idiyas.com/company/tekmira-pharmaceuticals

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…